Fresenius Kabi
As of the edition of 20 October 2026, Fresenius Kabi runs 39 drugs, 38 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 5 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 38 |
| Stopped | 1 |
| Total | 39 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Bupivacaine | none listed | 1 |
| Lidocaine | none listed | 2 |
| Bortezomib | none listed | 1 |
| Acetaminophen | none listed | 17 |
| Propofol | none listed | 0 |
| Ropivacaine | none listed | 2 |
| Fulvestrant | none listed | 1 |
| Oxytocin | none listed | 1 |
| Morphine | none listed | 2 |
| Moxifloxacin | none listed | 0 |
| Epinephrine | none listed | 23 |
| Magnesium sulfate anhydrous | none listed | 0 |
| Furosemide | none listed | 2 |
| Heparin | none listed | 5 |
| Rocuronium | none listed | 0 |
| Glycopyrronium | none listed | 10 |
| Atropine | none listed | 12 |
| Levothyroxine | none listed | 6 |
| Hydromorphone | none listed | 1 |
| Indomethacin | none listed | 3 |
| Palonosetron | none listed | 3 |
| Calcium | none listed | 0 |
| Glucagon | none listed | 2 |
| Tobramycin | none listed | 0 |
| Gonadotropin, chorionic | Ended 1985 (computed from the first US licence) | 0 |
A route B row is one company at one target. 13 more marketed drugs are not listed here.
Where its trials are
- Blood and lymph: 2 trials led
- Cancer: 2 trials led
- Immune system: 2 trials led